Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired resistance through activation of parallel compensatory pathways. We have pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Biol Sci
Autors principals: Bracht, Jillian Wilhelmina Paulina, Karachaliou, Niki, Berenguer, Jordi, Pedraz-Valdunciel, Carlos, Filipska, Martyna, Codony-Servat, Carles, Codony-Servat, Jordi, Rosell, Rafael
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854375/
https://ncbi.nlm.nih.gov/pubmed/31754333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.32889
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars